Table 2. Published studies demonstrate a strong correlation between elevated preoperative CA 19-9 serum levels and subsequent pancreatic cancer clinical stage. Eighty to 90% of patients with advanced pancreatic cancer (stage III-IV) will have a markedly elevated CA 19-9 serum level of >100 U/mL.
| Author, year | n | Stage (AJCC) |
CA 19-9 level (U/mL) |
|
|---|---|---|---|---|
| Mean | ||||
| Pleskow et al., 1989 (21) |
6 14 |
I-III IV |
1,522 20,720 |
|
| Safi et al., 1997 (22) |
29 8 47 13 |
I II III IV |
Median (range) |
|
| 68 (9.0-3,018) 72 (8.4-5,000) 210 (2-7,496) 412 (49.6-14,600) | ||||
| Jiang et al., 2004 (23) |
2 5 25 97 |
I II III IV |
Median±SD |
|
| 26.31±6.56 875.45±329.31 1223±479.73 2,018.19±731.36 | ||||
| Ferrone et al., 2006 (24) |
14 18 42 97 5 |
IA IB IIA IIB IV |
Median |
|
| 20.5 86 105 164 182 | ||||
| Kim et al., 2009 (25) |
4 32 23 20 33 |
IA IIA IIB III IV |
Mean |
Median ±SD |
| 40.05 469.64 747.79 709.98 3,239 |
40.05±23.85 469.64±1,055.86 747.79±2,044.71 709.98±1,392.65 3,239.06±4,074.25 |
|||
| Kondo et al., 2010 (26) | 11 98 |
I II-IV |
Median |
|
| 96 160 | ||||
AJCC: American Joint Commission on Cancer; U/mL: unit/milliliter; SD: standard deviation.